Supreet Agarwal, Lei Fang, Kerry McGowen, JuanJuan Yin, Joel Bowman, Anson T Ku, Aian Neil Alilin, Eva Corey, Martine P Roudier, Lawrence D True, Ruth F Dumpit, Ilsa Coleman, John K Lee, Peter S Nelson, Brian J Capaldo, Aida Mariani, Clare E Hoover, Ilya S Senatorov, Michael Beshiri, Adam G Sowalsky, Elaine M Hurt, Kathleen Kelly
Antibody-drug conjugates(ADCs) are promising targeted cancer therapy; however, patient selection based solely on target antigen expression without consideration for cytotoxic payload vulnerabilities has plateaued clinical benefits. Biomarkers to capture patients who might benefit from specific ADCs have not been systematically determined for any cancer. We present a comprehensive therapeutic and biomarker analysis of a B7H3-ADC with pyrrolobenzodiazepine(PBD) payload in 26 treatment-resistant, metastatic prostate cancer(mPC) models...
September 19, 2023: Journal of Clinical Investigation